Oncolix, Inc. (Oncolix) is a clinical-stage biotechnology company
We are developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer. This clinical trial began in 2016. Preliminary data from the first dosing group (the low dose) of this trial suggest Prolanta is safe with some evidence of efficacy in a patient population that is difficult to treat. Prolanta™ is a prolactin receptor antagonist that has demonstrated significant efficacy in xenograft models through a unique mechanism of action, autophagy (see Our Science). In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers.
The FDA has also approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow reduced filing fees, federal tax credits and marketing exclusivity by the FDA.
Proudly partnered with Greenville Health System
Oncolix, Inc. (Oncolix) is a bio-pharmaceutical company originally established at the Greenville Health System through the innovative efforts of the Oncology Research Institute in conjunction with the GHS Cancer Center drug discovery program. Oncolix, now based in Houston, Texas, is currently focusing on phase one clinical trials of Prolanta™ - a targeted therapeutic protein for the treatment of breast and ovarian cancer. Prolanta™ was pioneered within the Oncology Research Institute (now known as the Clemson Biomedical Institute) at GHS in Greenville, SC.
Proudly partnered with MD Anderson Cancer Treatment Center
MD Anderson has been ranked the No. 1 hospital for cancer care in the nation by U.S. News & World Report’s “Best Hospitals” survey.